The role of IL-6, HGF and TGFβ_1 in biliary epithelial cells carcinogenesis
The role of IL-6, HGF and TGFβ_1 in biliary epithelial cells carcinogenesis
批准号:
12671275
负责人:
YOKOMURO Shigeki
金额:
$1.86万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
2000
资助国家:
日本
项目状态:
已结题
起止时间:
2000 至 2002
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Intraheptatic chollagiocarcinoma (CC) and other cancers of the biliary tree, including the gallbladder, are often associated with non-neoplastic inflammatory diseases of the biliary tree, such as sclerosing cholangitis, clonorchiasis, and hepatolithiasis. These diseases also involve reparative, non-neoplastic biliary epithelial cell (BEC) proliferation. Unfortunately, although a significant number of biliary tract cancers arise under predictable conditions, they carry a poor prognosis because of difficulties in establishing the diagnosis before the tumors reach a noncurative stage. Earlier diagnosis and attempts at curative therapy will require a better understanding of the molecular mechanisms controlling reparative and cancerous BEC growth and the steps involved in a transition between the 2 processes. During non-neoplastic BEC repair like that seen with obstructive cholangiopathy, competing mitogenic and mitoinhibitory influences action on BECs, largely in a paracrine fashion, are a … More ccompanied by activation of periductal myofibroblasts and fibrogenesis. For example, the first several days to weeks afte biliary obstraction are characterized by explosive BEC proliferation. This is associated with up-regulation of hepatocyte growth factor (HGF) and interleukin 6 (IL-6) in the peribiliary stromal and hematolymphoid cells, and these same mediators stimulate non-neoplastic BEC DNA synthesis, in vitro. However, if the obstruction persists, BEC proliferation returns to near beseline levels and progressive fibrogenesis ensues. This occurs coincidently with tht induction of mitoinhibitory and fibrogenic growth factors, such as fibroblast growth factor and the TGF-b family of mitoinhibitory cytokines, including TGF-b1 and activin A. Receptros for these mitogens or mitoinhibitors, respectivily, are upregulated on the sruface of the BEC during successive stages of the response. The transition from reactive BEC to CC is accompanied by alterations that favor continued growth over mitoinhibition and apoptosis. Thus, malignancies can circumvent the effect s of mediators that inhibit growth or induce apoptosis, or acquire the ability to synthesize and secrete their own growth factor(s), superseding the normal paractine signaling with autocrine pathways. Less
期刊论文(3)
专著(0)
科研奖励(0)
会议论文
Shigeki Yokomuro: "Growth Control of Human Biliary Epithelial Cells by IL-6, HGF, TGFB, and Activin A"Hepatology. 32. 26-35 (2000)
Shigeki Yokomuro:“IL-6、HGF、TGFB 和激活素 A 对人胆管上皮细胞的生长控制”肝病学。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Shigeki Yokomuro: "Growth Control of Human Biliary Epithelial Cells by IL-6, HGF, TGFβ_1 and Activin."Hepatology. 32. 26-35 (2000)
Shigeki Yokomuro:“IL-6、HGF、TGFβ_1 和激活素对人胆管上皮细胞的生长控制”,《肝病学》32. 26-35 (2000)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
Shigeki Yokomuro: "Growth Control of human biliary epithelial cells by IL-6 HGF, TGFβ1 and Activin A."Hepatology. 32(1). 26-35 (2000)
Shigeki Yokomuro:“IL-6 HGF、TGFβ1 和激活素 A 对人胆管上皮细胞的生长控制”,Hepatology 32(1) (2000)。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
The effect for C-reactive protein (CRP) for sever sepsis
-
批准号:16K11424
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.08万
-
财政年份:2016
-
负责人:YOKOMURO Shigeki
-
依托单位:
Application of IL-6 HGF, TGF beta 1 for a bile duct cancer treatment.
-
批准号:15591450
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.11万
-
财政年份:2003
-
负责人:YOKOMURO Shigeki
-
依托单位:
国内基金
海外基金
登录
查看更多内容
早期滋养型肠内营养联合益生菌对重症卒中患者喂养耐受性及TNF-α/IL-6水平的影响研究
-
批准号:2026JJ81631
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:廖思思
-
依托单位:
七氟烷通过调控IL-6/FSP1轴抑制心肌铁死亡减轻心肌缺血再灌注损伤的机制研究
-
批准号:JCZRLH202601296
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
盐酸小檗碱抑制NF-κB/IL-6/STAT3信号通路重塑免疫微环境并增敏肺癌免疫治疗的研究
-
批准号:JCZRLH202600985
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
双歧杆菌与消退素RvD1协同调控IL-6/STAT3/Notch信号轴介导结肠癌EMT及免疫调节的机制研究
-
批准号:JCZRLH202601410
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
基于"热证可灸"理论的中药联合铺棉灸治疗带状疱疹急性期的临床疗效及对血清SP、β-EP、IL-6、IL-10、NSE水平的影响
-
批准号:2026JJ81075
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:黄迎春
-
依托单位:
基于“截断扭转”学说探讨凉膈散通过IL-6/STAT3/RORγt轴调控脓毒症Th17/Treg稳态的机制及临床研究
-
批准号:2026JJ82600
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:黄磊
-
依托单位:
基于IL-6/STAT3通路巨噬细胞极化调控免疫反应在胸膜结核瘤形成中的机制
-
批准号:2026JJ82516
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:张锋
-
依托单位:
早产儿脑白质损伤的 MRI 影像学特征联合炎症因子组合(IL-6、TNF-α、IL-1β)与神经系统损害关联研究
-
批准号:JCZRLH202601761
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位:
从肝失疏泄探讨肝脏代谢物介导IL-6/STAT3通路调控GABA能系统对睡眠节律影响的机制及逍遥散的干预作用
-
批准号:2026JJ30175
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:滕永杰
-
依托单位:
炎症因子组合(IL-6、TNF-α、IL-1β)动态监测在极低出生体重儿坏死性小肠结肠炎早期预测中的价值研究
-
批准号:JCZRLH202601488
-
项目类别:省市级项目
-
资助金额:--
-
批准年份:2026
-
负责人:
-
依托单位: